Vasoactive Intestinal Peptide Tumor Industry Valued at $2.04 Billion by 2029 With CAGR of 6.2% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Vasoactive Intestinal Peptide Tumor Market from 2024 to 2025?
In recent times, the market for vasoactive intestinal peptide tumor has significantly expanded. The market, valued at $1.51 billion in 2024, is projected to increase to $1.61 billion in 2025 with a compound annual growth rate (CAGR) of 6.5%. The historical growth has been driven by a number of factors including a higher incidence of VIP tumors, emphasis on research and development activities, improved health consciousness, enhanced healthcare facilities, and partnerships between biotechnology companies and research organizations.
What Is the Projected Market Size of the Vasoactive Intestinal Peptide Tumor Market?
Over the next few years, the market for vasoactive intestinal peptide tumor is projected to witness substantial growth, reaching a value of $2.05 billion by 2029 with a compound annual growth rate (CAGR) of 6.3%. The proliferation during the forecast period is likely due to the growing demand for chemotherapy, quick drug approvals, increased preference for oral medications, heightened disease awareness, and rising tumor prevalence. The period’s significant trends encompass improvements in targeted therapies, progress in diagnosis methods, developments in treatment avenues, customized medicine, targeted care strategies and novel product introductions.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23561&type=smp
Who are the Major Competitors in the Vasoactive Intestinal Peptide Tumor Market Outlook?
Major companies operating in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Labcorp Holdings Inc., Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, NuView Life Sciences Inc., DNA Labs India, Inter Science Institute, Ulta Lab Tests, True Health Labs, Ganesh Diagnostic, Agilus Diagnostics.
What Is Fueling Growth in the Vasoactive Intestinal Peptide Tumor Market?
The advancement in targeted therapies is anticipated to fuel the growth of the vasoactive intestinal peptide tumor market. These therapies aim at distinct molecules or pathways implicated in disease progression, particularly cancer, to selectively combat abnormal cells while sparing healthy ones. The popularity of such therapies is spurred by precision medicine, which optimizes efficacy by pinpointing specific genetic mutations and lessening side effects. VIP tumors are treated with targeted therapies by inhibiting vital pathways that stimulate tumor growth and hormone secretion. This reduces VIP levels, alleviates effects like severe diarrhea and slows down the progression of the disease. For example, in July 2024, based on data from the American Society of Gene and Cell Therapy (ASGCT), a US professional membership organization, the second quarter of 2024 witnessed 76 gene therapy trials commencement, marking a 25% increase compared to the preceding quarter. These factors contribute to the rise of targeted therapy, which propels the growth of the vasoactive intestinal peptide tumor market. The enhanced detection due to the growing prevalence and awareness of neuroendocrine tumors fuels the market growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23561&type=smp
Which Vasoactive Intestinal Peptide Tumor Market Segments Are Growing the Fastest?
The vasoactive intestinal peptide tumor market covered in this report is segmented –
1) By Treatment: Surgical Intervention, Radiotherapy, Chemotherapy, Targeted Therapy
2) By Diagnosis: Imaging Techniques, Biopsy, Endoscopic Ultrasound
3) By Therapeutic Approach: Palliative Care, Curative Treatment, Adjuvant Treatment
4) By End-User: Hospitals, Cancer Specialty Clinics, Diagnostic Laboratories
Subsegments:
1) By Surgical Intervention: Tumor Resection, Debulking Surgery, Minimally Invasive Surgery
2) By Radiotherapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy
3) By Chemotherapy: Cytotoxic Chemotherapy, Combination Chemotherapy, Adjuvant And Neoadjuvant Chemotherapy
4) By Targeted Therapy: Somatostatin Analog Therapy, Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies
Which Industry Trends Are Shaping the Future of the Vasoactive Intestinal Peptide Tumor Market?
In an effort to enhance treatment efficacy, improve patient adherence, and offer prolonged symptomatic relief, leading companies active in the vasoactive intestinal peptide tumor market are concentrating on developing superior products like long-acting injectable suspensions. These suspensions, which slowly release their active ingredients over a longer duration, reduce the need for repeated dosing. For example, in October 2024, the US-based Teva Pharmaceutical Industries Ltd., introduced the first and exclusive generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the U.S. This drug is for long-term maintenance treatment in acromegaly patients who did not respond adequately to surgery or radiotherapy. It also manages severe diarrhea and flushing connected with metastatic carcinoid tumors and VIP-secreting tumors. The product’s introduction underpins Teva’s proficiency in complex generics, and aids in strengthening its footing in the generic pharmaceuticals market.
Access The Full Report Here:
Which Countries Are Leading the Vasoactive Intestinal Peptide Tumor Market?
North America was the largest region in the vasoactive intestinal peptide tumor market in 2024. The regions covered in the vasoactive intestinal peptide tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23561
This Report Delivers Insight On:
1. How big is the vasoactive intestinal peptide tumor market, and how is it changing globally?
2. Who are the major companies in the vasoactive intestinal peptide tumor market, and how are they performing?
3. What are the key opportunities and risks in the vasoactive intestinal peptide tumor market right now?
4. Which products or customer segments are growing the most in the vasoactive intestinal peptide tumor market?
5. What factors are helping or slowing down the growth of the vasoactive intestinal peptide tumor market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
